Scherr Douglas S, Pitts W Reid
James Buchanan Brady Foundation, Department of Urology, New York-Presbyterian Hospital/Weill Medical College of Cornell University, 525 East 68th Street, Starr 900, New York, NY 10021, USA.
J Urol. 2003 Nov;170(5):1703-8. doi: 10.1097/01.ju.0000077558.48257.3d.
During the last 2 decades there has been an increase in the number of men with prostate cancer placed on luteinizing hormone releasing hormone (LH-RH) agonist therapy. In addition, the duration of individual therapy has extended from what was once only a few months to, in many cases, several years. As a result there has been an increase in the incidence of side effects, including osteoporosis, decreased cognitive abilities, vascular stiffness and fatigue. We explored the use of estrogen in the form of diethylstilbestrol (DES) as an alternative treatment for men with prostate cancer, and introduce the concept of androgen deprivation without estrogen deprivation. In doing so we hope to elucidate some of the nonhormonal nonsteroidal effects of DES. Furthermore, we hope to define the mechanisms by which DES can be useful when LH-RH agonist therapy or orchiectomy has failed.
We comprehensively reviewed the literature from 1935 to the present regarding estrogen and antiandrogen therapy. Our search focused on issues pertaining to side effects, efficacy and nonsteroidal effects of antiandrogens and estrogens.
It is readily apparent from the literature that androgen deprivation with DES can achieve effective prostate cancer control with demonstrable benefits compared to conventional LH-RH agonist therapy. In particular, rates of bone resorption and osteoporosis are less with the use of estrogen therapies. Estrogen has a clear beneficial effect on cognitive function. The estrogen metabolite 2-methoxyestradiol has significant antiangiogenic and pro-apoptotic effects. These effects give estrogens an added anticancer effect not otherwise seen in conventional LH-RH agonist therapy.
The efficacy of 1 mg DES extends well beyond its androgen suppressive effects. Androgen deprivation without estrogen deprivation is a concept that deserves further attention in the urological community.
在过去20年中,接受促黄体生成素释放激素(LH-RH)激动剂治疗的前列腺癌男性患者数量有所增加。此外,个体治疗的持续时间已从曾经的仅几个月延长至在许多情况下的数年。结果,副作用的发生率有所增加,包括骨质疏松、认知能力下降、血管僵硬和疲劳。我们探索了以己烯雌酚(DES)形式使用雌激素作为前列腺癌男性患者的替代治疗方法,并引入了无雌激素剥夺的雄激素剥夺概念。通过这样做,我们希望阐明DES的一些非激素非甾体作用。此外,我们希望确定在LH-RH激动剂治疗或睾丸切除术失败时DES可能有用的机制。
我们全面回顾了1935年至今关于雌激素和抗雄激素治疗的文献。我们的搜索重点是与抗雄激素和雌激素的副作用、疗效及非甾体作用相关的问题。
从文献中很明显可以看出,与传统的LH-RH激动剂治疗相比,用DES进行雄激素剥夺可以有效控制前列腺癌并具有明显益处。特别是,使用雌激素疗法时骨吸收和骨质疏松的发生率较低。雌激素对认知功能有明显的有益作用。雌激素代谢物2-甲氧基雌二醇具有显著的抗血管生成和促凋亡作用。这些作用赋予雌激素一种传统LH-RH激动剂治疗中未见到的额外抗癌效果。
1毫克DES的疗效远远超出其雄激素抑制作用。无雌激素剥夺的雄激素剥夺是一个值得泌尿外科界进一步关注的概念。